finance News

Poland will spend over PLN 700 million (EUR 154.8 million) in 2021-2023 to cure rare diseases as a part of the Rare Disease Plan, the health minister has announced on Monday. Currently, the Plan defines 40 specific tasks and deadlines for their implementation, worth over PLN 90 million (EUR 19.8...
LYON, France – POXEL SA (Euronext – POXEL – FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare disorders, today announced a new strategic direction to focus its pipeline on high value, rare metabolic indications and NASH, with...
OKLAHOMA CITY – Progentec, a leader in diagnostic and digital technologies for the proactive management of autoimmune diseases, announced today an 18-month collaborative research agreement with GlaxoSmithKline (GSK) to evaluate novel measurement and management tools for systemic lupus erythematosus (“SLE” or “lupus”). At least 5 million people worldwide are living with...
LEIDEN, Netherlands & CAMBRIDGE, Mass. –  ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR),  announced a global licensing and research collaboration with Eli Lilly and Company (Lilly) focused on the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The companies will use ProQR’s...
RARE-X, a collaborative platform for patient-controlled data collection, global data sharing and analysis, is partnering with the Broad Institute of MIT and Harvard to advance and support the discovery of new treatments for 9,500 rare diseases, including Lambert-Eaton myasthenic syndrome (LEMS). The collaboration will leverage Broad Institute’s technology to assist in patient data collection...